BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8436 related articles for article (PubMed ID: 23928105)

  • 21. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation.
    Orellana-Gavaldà JM; Herrero L; Malandrino MI; Pañeda A; Sol Rodríguez-Peña M; Petry H; Asins G; Van Deventer S; Hegardt FG; Serra D
    Hepatology; 2011 Mar; 53(3):821-32. PubMed ID: 21319201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effects of Rubi Fructus extracts on hepatic steatosis development in high-fat diet-induced obese mice.
    Nam MK; Choi HR; Cho JS; Cho SM; Ha KC; Kim TH; Ryu HY; Lee YI
    Mol Med Rep; 2014 Oct; 10(4):1821-7. PubMed ID: 25050832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of hepatic sterol regulatory element-binding protein-1c-mediated gene expression contributes to Salacia oblonga root-elicited improvement of fructose-induced fatty liver in rats.
    Liu L; Yang M; Lin X; Li Y; Liu C; Yang Y; Yamahara J; Wang J; Li Y
    J Ethnopharmacol; 2013 Dec; 150(3):1045-52. PubMed ID: 24157375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insights of dietary polyphenols and obesity.
    Wang S; Moustaid-Moussa N; Chen L; Mo H; Shastri A; Su R; Bapat P; Kwun I; Shen CL
    J Nutr Biochem; 2014 Jan; 25(1):1-18. PubMed ID: 24314860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.
    Ohyama T; Sato K; Yamazaki Y; Hashizume H; Horiguchi N; Kakizaki S; Mori M; Kusano M; Yamada M
    World J Gastroenterol; 2014 Nov; 20(43):16227-35. PubMed ID: 25473177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.
    Gómez-Zorita S; Fernández-Quintela A; Macarulla MT; Aguirre L; Hijona E; Bujanda L; Milagro F; Martínez JA; Portillo MP
    Br J Nutr; 2012 Jan; 107(2):202-10. PubMed ID: 21733326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
    Goetzman ES; Tian L; Wood PA
    Mol Genet Metab; 2005 Jan; 84(1):39-47. PubMed ID: 15639194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
    Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
    Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels.
    Dahlhoff C; Worsch S; Sailer M; Hummel BA; Fiamoncini J; Uebel K; Obeid R; Scherling C; Geisel J; Bader BL; Daniel H
    Mol Metab; 2014 Aug; 3(5):565-80. PubMed ID: 25061561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.
    Perfield JW; Ortinau LC; Pickering RT; Ruebel ML; Meers GM; Rector RS
    J Obes; 2013; 2013():296537. PubMed ID: 23401753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
    Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
    Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
    Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
    Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
    Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 422.